iPS cell derived cardiomyocytes
iPS cell derived cardiomyocytes are required in fields such as regenerative medicine and drug discovery.
Heart disease is the leading cause of death in the world. Donor shortage and immune rejection are problems in heart transplantation and surgical operation, and transplantation therapy using iPS cell derived cardiomyocytes is expected.
In addition, many merits are expected by incorporating the test using this iPS cell-derived cardiomyocyte into drug discovery. In addition, there is also the demand for its use in drug discovery and for basic research.
In the process of cardiomyocyte differentiation from iPS cells, we have replaced all of the protein in the culture solution with low molecular-weight compounds, and have succeeded in a significant reduction of medium cost (approximately 1/100).
We believe that this protein-free technology, one of our core technologies, can also be applied to the development of other regenerative medicine products and is not limited to specific cell types such as iPS cells and cardiomyocytes. We have a track record of research and development in several different cell types to date.
High maturity · High purity
We have been able to produce mature cardiomyocytes and highly pure cardiomyocytes with stable properties by using mass culture technique.
The animation is about 1 cm iPS cell-derived cardiomyocyte sheet.
Good drug response
Our cardiomyocytes show drug responsiveness peculiar to mature cardiac muscles.
Highly engrafted cardiomyocytes
As a result of transplantation experiments in rats, Myoridge cardiomyocytes have been found to be highly engrafted cardiomyocytes.